TITLE

AMD: A Revolution In Therapy Begins

AUTHOR(S)
Rosenfeld, Philip
PUB. DATE
March 2005
SOURCE
Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that affect the eye; Characteristics of Macugen; Therapies that comprise the anti-VEGF therapeutic technique; Various approaches for attacking VEGF; Clinical trials that focus on anti-VEGF therapeutic techniques. INSETS: Untitled;Self-Assessment Questions.
ACCESSION #
16468490

 

Related Articles

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • An Update on Macugen Trials. Kulkarni, Kaushal; Prenner, Jonathan L. // Review of Ophthalmology;Dec2005, Vol. 12 Issue 12, Special section p6 

    The article presents information on the VEGF Inhibition Study in Ocular Neovascularization (VISION) study in its second year and on a trial of Macugen for diabetic macular edema. Macugen is used in curing exudative Age-related Macular Degeneration. It is also known as pegaptanib sodium and is...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...

  • New Drug Treats Age-Related Macular Degeneration.  // FDA Consumer;Mar/Apr2005, Vol. 39 Issue 2, p4 

    Announces the approval given by the U.S. Food and Drug Administration to the drug Macugen from Eyetech Pharmaceuticals Inc. and Pfizer Inc. to slow vision loss in people with wet age-related macular degeneration (AMD). Overview of the therapeutic application of the drug targeting vascular...

  • Study: quarterly dosing of ranibizumab may not be as effective as monthly dosing. Talsma, Julia // Ophthalmology Times;1/1/2007, Vol. 32 Issue 1, p44 

    The article discusses results of the PIER study that reveal that an initial dosing regimen of monthly ranibizumab injections followed by quarterly dosing of the anti-VEGF agent provided effective treatment for neovascular age-related macular degeneration. However, visual acuity benefits in the...

  • Vascular Endothelial Growth Factor: A New Frontier in Macular Degeneration. Gerson, Jeffry // Review of Optometry;11/15/2006 Part 2 of 2, Vol. 143, p4 

    The article provides an overview of the anti-vascular endothelial growth factor therapies that aid in the treatment of patients with age-related macular degeneration in the U.S. Drug treatments approved by the U.S. Food and Drug Administration, which have been discovered to be efficacious, are...

  • VEGF Trap-Eye is Safe, Effective. Shechtman, Diana L.; Karpecki, Paul M. // Review of Optometry;3/15/2012, Vol. 149 Issue 3, p112 

    The article focuses on studies which examine the efficacy and safety of the U.S. Food and Drug Administration (FDA)-approved Eylea or vascular endothelial growth factor (VEGF) Trap-Eye ophthalmic drug to treat wet age-related macular degeneration (AMD). These studies performed two clinical...

  • Intravitreal anti-VEGF drugs are step forward in AMD management. Charters, Lynda // Ophthalmology Times;12/15/2005, Vol. 30 Issue 24, p1 

    The article reports on the success of the development of the anti-vascular endothelial growth factor treatments for age-related macular degeneration (AMD). According to retina specialist Charles Schepens, the introduction of pegaptanib sodium and the clinical trial data of ranibizumab indicated...

  • Anti-PDGF found safe. Krader, Cheryl Guttman; Ho, Allen C. // Ophthalmology Times;4/15/2010, Vol. 35 Issue 8, p44 

    The article discusses the result of the phase I clinical study of Ophthotec's E10030 anti-platelet-derived growth factor aptamer for the treatment of neovascular age-related macular degeneration (AMD). It was found that E10030 is well-tolerated when used with anti-vascular endothelial growth...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics